Ascendis Pharma A/S
ASND
186 hedge funds and large institutions have $8.05B invested in Ascendis Pharma A/S in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 69 increasing their positions, 68 reducing their positions, and 23 closing their positions.
371% more call options, than puts
Call options by funds: $110M | Put options by funds: $23.3M
30% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 23
25% more funds holding in top 10
Funds holding in top 10: 16 → 20 (+4)
17% more capital invested
Capital invested by funds: $6.89B → $8.05B (+$1.16B)
2% more funds holding
Funds holding: 182 → 186 (+4)
1% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 68
1.51% less ownership
Funds ownership: 117.12% → 115.61% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$92.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$47.6M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$44.2M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$29M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$28.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$71.8M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$70.9M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$48.3M |
| 4 |
Goldman Sachs
New York
|
-$39.3M |
| 5 |
SCM
Spyglass Capital Management
San Francisco,
California
|
-$27.3M |
ASND Hedge Fund Activity: Q4 2022 in Review
186 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2022, worth a combined $8.05B — up 17% from $6.89B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ASND positions and 23 closed out — a net gain of 7 holders — while 69 added to existing stakes and 68 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $92.4M. The largest seller was Wellington Management Group, cutting an estimated $71.8M.
- 186 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2022, up from 182 in Q3 2022.
- Funds reported $8.05B of Ascendis Pharma A/S stock for Q4 2022, up 17% quarter-over-quarter.
- 30 funds opened new Ascendis Pharma A/S positions in Q4 2022 and 23 closed out, a net change of +7 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2022 was T. Rowe Price Investment Management, an estimated $92.4M added.
- The largest Ascendis Pharma A/S seller in Q4 2022 was Wellington Management Group, an estimated $71.8M sold.
Based on aggregated 13F filings for Q4 2022.